Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891138932> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W2891138932 abstract "TPS9597 Background: Uveal melanoma (UM) is a rare subtype of melanoma with no effective therapy for advanced disease. UM is characterized by mutations in GNAQ and GNA11 leading to constitutive activation of the mitogen activated protein kinase (MAPK) pathway. We have previously shown that targeting the MAPK pathway though MEK inhibition with Selumetinib (AZD6244, ARRY-142886) using a continuous dosing schedule improved progression free survival (PFS) in a randomized Phase II study of Selumetininb versus chemotherapy in patients with metastatic UM; however, no PFS or overall survival (OS) benefit was observed in a subsequent randomized Phase III study of Selumetinib and chemotherapy versus chemotherapy alone. We hypothesize that an intermittent dosing schedule of Selumetinib may be more effective than continuous dosing by achieving higher dose levels, better drug tolerability, and more complete target inhibition. We propose a Phase Ib study of Selumetinib in UM using an intermittent dosing schedule. Methods: A total of 28 subjects will be enrolled using the time to event continual reassessment method (TITE-CRM). Key inclusion criteria include a diagnosis of advanced UM, measurable disease by RECIST v1.1, and no prior MEK inhibitor therapy. Eligible subjects will be treated with Selumetinib starting at a dose level of 125 mg orally twice a day, using a 3-days-on and 4-days-off per week schedule. The primary goal of this study is to estimate the maximum tolerated dose (MTD) of intermittently dosed Selumetinib. Secondary endpoints are response rate, PFS and OS. Responses will be evaluated every 8 weeks by a CT scan of the chest and CT or MRI of the abdomen/ pelvis using RECIST v1.1 criteria. Mandatory tumor biopsies will be obtained at baseline, cycle 1 day 3 (Selumetinib-on day), and between cycle 1 day 11-14 (Selumetinib-off day) in 20 subjects, and optionally at progression. Tumor tissue will be assessed for MAPK pathway inhibition and reactivation at each time point, as well as mechanisms of resistance. Recruitment is currently ongoing. Clinical trial information: NCT02768766." @default.
- W2891138932 created "2018-09-27" @default.
- W2891138932 creator A5006913373 @default.
- W2891138932 creator A5006994766 @default.
- W2891138932 creator A5009086978 @default.
- W2891138932 creator A5014234217 @default.
- W2891138932 creator A5017491012 @default.
- W2891138932 creator A5025627271 @default.
- W2891138932 creator A5026962347 @default.
- W2891138932 creator A5034055406 @default.
- W2891138932 creator A5035218748 @default.
- W2891138932 creator A5038275385 @default.
- W2891138932 creator A5039325829 @default.
- W2891138932 creator A5040291209 @default.
- W2891138932 creator A5063370625 @default.
- W2891138932 creator A5072276912 @default.
- W2891138932 creator A5086473468 @default.
- W2891138932 date "2017-05-20" @default.
- W2891138932 modified "2023-09-30" @default.
- W2891138932 title "Multi-center phase Ib study of intermittent dosing of the MEK inhibitor, selumetinib, in patients with advanced uveal melanoma not previously treated with a MEK inhibitor." @default.
- W2891138932 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.tps9597" @default.
- W2891138932 hasPublicationYear "2017" @default.
- W2891138932 type Work @default.
- W2891138932 sameAs 2891138932 @default.
- W2891138932 citedByCount "0" @default.
- W2891138932 crossrefType "journal-article" @default.
- W2891138932 hasAuthorship W2891138932A5006913373 @default.
- W2891138932 hasAuthorship W2891138932A5006994766 @default.
- W2891138932 hasAuthorship W2891138932A5009086978 @default.
- W2891138932 hasAuthorship W2891138932A5014234217 @default.
- W2891138932 hasAuthorship W2891138932A5017491012 @default.
- W2891138932 hasAuthorship W2891138932A5025627271 @default.
- W2891138932 hasAuthorship W2891138932A5026962347 @default.
- W2891138932 hasAuthorship W2891138932A5034055406 @default.
- W2891138932 hasAuthorship W2891138932A5035218748 @default.
- W2891138932 hasAuthorship W2891138932A5038275385 @default.
- W2891138932 hasAuthorship W2891138932A5039325829 @default.
- W2891138932 hasAuthorship W2891138932A5040291209 @default.
- W2891138932 hasAuthorship W2891138932A5063370625 @default.
- W2891138932 hasAuthorship W2891138932A5072276912 @default.
- W2891138932 hasAuthorship W2891138932A5086473468 @default.
- W2891138932 hasConcept C121608353 @default.
- W2891138932 hasConcept C126322002 @default.
- W2891138932 hasConcept C143998085 @default.
- W2891138932 hasConcept C184235292 @default.
- W2891138932 hasConcept C2776087337 @default.
- W2891138932 hasConcept C2777288759 @default.
- W2891138932 hasConcept C2777658100 @default.
- W2891138932 hasConcept C2781187634 @default.
- W2891138932 hasConcept C2781249067 @default.
- W2891138932 hasConcept C502942594 @default.
- W2891138932 hasConcept C526805850 @default.
- W2891138932 hasConcept C57074206 @default.
- W2891138932 hasConcept C71924100 @default.
- W2891138932 hasConcept C86803240 @default.
- W2891138932 hasConcept C95444343 @default.
- W2891138932 hasConcept C98274493 @default.
- W2891138932 hasConceptScore W2891138932C121608353 @default.
- W2891138932 hasConceptScore W2891138932C126322002 @default.
- W2891138932 hasConceptScore W2891138932C143998085 @default.
- W2891138932 hasConceptScore W2891138932C184235292 @default.
- W2891138932 hasConceptScore W2891138932C2776087337 @default.
- W2891138932 hasConceptScore W2891138932C2777288759 @default.
- W2891138932 hasConceptScore W2891138932C2777658100 @default.
- W2891138932 hasConceptScore W2891138932C2781187634 @default.
- W2891138932 hasConceptScore W2891138932C2781249067 @default.
- W2891138932 hasConceptScore W2891138932C502942594 @default.
- W2891138932 hasConceptScore W2891138932C526805850 @default.
- W2891138932 hasConceptScore W2891138932C57074206 @default.
- W2891138932 hasConceptScore W2891138932C71924100 @default.
- W2891138932 hasConceptScore W2891138932C86803240 @default.
- W2891138932 hasConceptScore W2891138932C95444343 @default.
- W2891138932 hasConceptScore W2891138932C98274493 @default.
- W2891138932 hasLocation W28911389321 @default.
- W2891138932 hasOpenAccess W2891138932 @default.
- W2891138932 hasPrimaryLocation W28911389321 @default.
- W2891138932 hasRelatedWork W2057629729 @default.
- W2891138932 hasRelatedWork W2104148147 @default.
- W2891138932 hasRelatedWork W2144096834 @default.
- W2891138932 hasRelatedWork W2315134770 @default.
- W2891138932 hasRelatedWork W2322323136 @default.
- W2891138932 hasRelatedWork W2560580763 @default.
- W2891138932 hasRelatedWork W2602918057 @default.
- W2891138932 hasRelatedWork W2606457520 @default.
- W2891138932 hasRelatedWork W2783448198 @default.
- W2891138932 hasRelatedWork W2800413015 @default.
- W2891138932 hasRelatedWork W2890461491 @default.
- W2891138932 hasRelatedWork W2909618481 @default.
- W2891138932 hasRelatedWork W2938280489 @default.
- W2891138932 hasRelatedWork W2939704270 @default.
- W2891138932 hasRelatedWork W2945676496 @default.
- W2891138932 hasRelatedWork W2945871854 @default.
- W2891138932 hasRelatedWork W2967405601 @default.
- W2891138932 hasRelatedWork W3008022698 @default.
- W2891138932 hasRelatedWork W3029236280 @default.
- W2891138932 hasRelatedWork W3170976681 @default.
- W2891138932 isParatext "false" @default.
- W2891138932 isRetracted "false" @default.
- W2891138932 magId "2891138932" @default.
- W2891138932 workType "article" @default.